Dyne Therapeutics, Inc. (DYN)
Chart Events
Performance Outlook
| Previous Close | 12.26 |
| Open | 12.01 |
| Bid | 11.91 x 800 |
| Ask | 12.00 x 800 |
| Day's Range | 11.63 - 12.33 |
| 52 Week Range | 4.30 - 17.89 |
| Volume | |
| Avg. Volume | 212,832 |
| Market Cap | 618.079M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.11 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DYN
Related Research
- Dyne Therapeutics, Inc.The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.RatingFair ValueEconomic Moat22 hours agoArgus Research
- GlobeNewswire
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the publication of Duchenne muscular dystrophy (DMD) preclinical data in a “Breakthrough Article” in Nucleic Acids Resear
- GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2022 and business highlights. “We are executing on our glob
- Zacks
Best Momentum Stocks to Buy for July 18th
DINO, DYN, and DLNG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 18, 2022.
